Tagged with association

Greece Michalis Massourakis, Chief Economist at the Federation of Greek Industries (SEV) provides his expert insights on the roles and functions of the organization, the economic and political situation in Greece, and how the country is managing to implement policies to boost the economy and transition out of the crisis. To…

Greece With a dual role as the president of SFEE (Hellenic Association of Pharmaceutical Companies) and the General Manager of one of the most innovative biopharmaceutical companies in the world, Abbvie, Pascal Apostolides candidly discusses the milestones of Abbvie as an independent company, the impact of clawbacks and rebates in the…

Switzerland With a population of only 350,000, Ticino has a remarkably well developed pharmaceutical cluster. FIT Chairman Giorgio Calderari explains that the cluster’s key strength lies in the diverse range of capabilities which its members are able to offer as contract services to one another, and of course other interested third…

Greece General Manager of the Hellenic Association of Pharmaceutical Companies (SFEE), Mihalis Himonas speaks about his role spearheading Greece’s main pharma association, the contribution of the pharma industry to GDP, market access challenges, and solutions for creating a sustainable healthcare environment. As the organization representing the united voice of the pharmaceutical…

Greece As the President of the Panhellenic Union of Pharmaceutical Industries (PEF), Theodore Tryfon shares the mission of the association, the main challenges plaguing the sector, as well as the measures in place to mitigate the difficult economic times and elevate the Greek brand in the upcoming years. As an introduction…

Switzerland The President of FASMED—the Swiss medical technology industry and trade association—elaborates on the plans to join forces with Medical Cluster, the other national medical technology organization, and highlights the current challenges facing the industry in Switzerland. Mr Gasche, you have a very interesting background, in the sense that you have…

Switzerland The Swiss Biotech Association’s Nic Alexakis describes Switzerland’s thriving biotech scene and extensive support infrastructure, while also highlighting the gaps around early stage funding and the ability of different cantons to collaborate on economic development.  Switzerland of course has quite the reputation as a hub for biotech activity – how…

Switzerland For the eighth year in a row the World Economic Forum has ranked Switzerland first in both global competitiveness and in innovation; economiesuisse CEO Monika Rühl discusses the main issues which threaten this leading position, and the overall growth prospects for the Swiss economy. To begin, could you please introduce…

Luxembourg Founded just five years ago, the Luxembourg Pharmaceutical Association (APL) was created in response to the divergence of Luxembourg’s pharmaceutical regulatory environment with Belgium. At present, Secretary General Hendrik Kühne’s primary objective is to build a stronger dialogue and greater trust with the authorities, such that the industry can be…

Switzerland Walter P. Hölzle, president of vips, discusses the current priorities of the association, the importance of innovation, and the challenges of the current pricing system. While growth is close to zero for many pharmaceutical markets in Europe, Swiss pharma spending increased 4.5 percent in 2015. What would you identify as…

Philippines Higinio “JP” Porte, president of the Philippine Pharmaceutical Manufacturers Association, discusses how his extensive pharmaceutical background led him to his current role as well as the main objectives of the association moving forward. He also discusses his work to create comradery within the association, fostering an environment where members are…

Mexico Mayra Galindo Leal, general director of the Mexican Association of the Fight Against Cancer (AMLCC) provides an overview of the main milestones of this association that stands as the most important patient organization for cancer in Mexico, her expectations towards the pharmaceutical industry, and the main challenges she faces when…